Becton Dickinson and Co (BDX) Stock Price
Becton Dickinson and Co Price
Revenue has compounded at 7.3% per year over the past 19 years to 21.84 B USD. Earnings per share have grown at 3.7% per year over the last 19 years. Becton Dickinson and Co's net margin stands at 7.7%, down from 10.9% several years earlier. Becton Dickinson and Co currently offers a dividend yield of about 2.27%. The payout ratio is around 71% of earnings. The dividend has grown at 8.5% per year over the past 19 years. Analysts set a median price target of 190.00 USD, implying 3.4% above the current price. Of 21 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 29% above its 52-week low.
Becton Dickinson and Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Becton Dickinson and Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Becton Dickinson and Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Becton Dickinson and Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Becton Dickinson and Co Price |
|---|---|
| 9/25/2026 | 183.82 USD |
| 9/24/2026 | 179.23 USD |
| 9/23/2026 | 182.52 USD |
| 9/22/2026 | 181.88 USD |
| 9/21/2026 | 180.67 USD |
| 9/18/2026 | 180.33 USD |
| 9/17/2026 | 181.38 USD |
| 9/16/2026 | 185.28 USD |
| 9/15/2026 | 183.91 USD |
| 9/14/2026 | 179.76 USD |
| 9/11/2026 | 175.99 USD |
| 9/10/2026 | 177.17 USD |
| 9/9/2026 | 179.80 USD |
| 9/8/2026 | 179.70 USD |
| 9/4/2026 | 186.73 USD |
| 9/3/2026 | 187.62 USD |
| 9/2/2026 | 187.52 USD |
| 9/1/2026 | 187.12 USD |
| 8/31/2026 | 188.58 USD |
| 8/28/2026 | 189.38 USD |
| 8/27/2026 | 190.31 USD |
| 8/26/2026 | 190.21 USD |
| 8/25/2026 | 189.78 USD |
| 8/24/2026 | 191.00 USD |
| 8/21/2026 | 192.00 USD |
| 8/20/2026 | 187.62 USD |
| 8/19/2026 | 186.06 USD |
| 8/18/2026 | 182.21 USD |
| 8/14/2026 | 183.40 USD |
| 8/13/2026 | 181.97 USD |
Becton Dickinson and Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.28 | 12.48 | 12.09 | 15.98 | 17.29 | 16.07 | 19.13 | 18.87 | 19.37 | 20.18 | 21.84 | 19.29 | 19.69 | 20.44 | 21.13 | 21.91 |
| 21.74 | 21.41 | -3.12 | 32.17 | 8.18 | -7.03 | 19.02 | -1.36 | 2.66 | 4.16 | 8.23 | -11.67 | 2.08 | 3.79 | 3.40 | 3.66 |
| 45.66 | 47.99 | 49.33 | 45.48 | 47.94 | 42.29 | 45.12 | 44.92 | 42.17 | 45.22 | 45.44 | 45.44 | 45.44 | 45.44 | 45.44 | 45.44 |
| 4.70 | 5.99 | 5.97 | 7.27 | 8.29 | 6.80 | 8.63 | 8.48 | 8.17 | 9.13 | 9.92 | 8.77 | 8.95 | 9.29 | 9.60 | 9.95 |
| 1.07 | 1.43 | 1.50 | 1.51 | 1.76 | 0.91 | 2.25 | 2.28 | 2.11 | 2.40 | 2.58 | 4.33 | 4.70 | 4.75 | 5.25 | 5.60 |
| 10.45 | 11.46 | 12.38 | 9.44 | 10.18 | 5.67 | 11.76 | 12.09 | 10.90 | 11.88 | 11.80 | 22.46 | 23.86 | 23.25 | 24.85 | 25.55 |
| 0.70 | 0.98 | 1.10 | 0.31 | 1.23 | 0.87 | 2.09 | 1.78 | 1.48 | 1.71 | 1.68 | 3.66 | 3.83 | 4.09 | 4.39 | 4.72 |
| -41.35 | 40.43 | 12.70 | -71.73 | 296.46 | -29.12 | 139.36 | -14.96 | -16.58 | 14.89 | -1.58 | 117.82 | 4.90 | 6.65 | 7.43 | 7.38 |
| 3.06 | 2.71 | 2.94 | 3.02 | 3.10 | 3.20 | 3.36 | 3.52 | 3.68 | 3.89 | 4.17 | 4.20 | 4.40 | 4.61 | – | – |
| 36.61 | -11.44 | 8.49 | 2.72 | 2.65 | 3.23 | 5.00 | 4.76 | 4.55 | 5.71 | 7.20 | 0.72 | 4.76 | 4.77 | – | – |
| 216.29 | 217.74 | 230.04 | 274.26 | 274.95 | 293.11 | 286.72 | 285.34 | 291.40 | 290.39 | 285.07 | 285.07 | 285.07 | 285.07 | 285.07 | 285.07 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Becton Dickinson and Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Becton Dickinson and Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Becton Dickinson and Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Becton Dickinson and Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Becton Dickinson and Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Becton Dickinson and Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co business model & stock analysis
Becton Dickinson and Co SWOT Analysis
Strengths
1. Market leader: Becton Dickinson (BD) is a well-established and recognized company with a significant market share in the medical technology industry.
2. Diverse product portfolio: BD offers a wide range of medical devices, diagnostics, and healthcare solutions, catering to various healthcare needs.
3. Strong research and development (R&D): The company invests heavily in R&D, leading to innovative product offerings and technological advancements.
Weaknesses
1. Product recalls: Like any other company in the industry, BD has faced product recall issues in the past, which can dent its reputation and consumer trust.
2. High dependence on key customers: BD relies on a few major customers for a significant portion of its revenue, exposing it to potential revenue fluctuations.
3. Increased competition: The medical technology space is highly competitive, with numerous competitors striving to gain market share.
Opportunities
1. Growing healthcare industry: The healthcare sector's continuous expansion offers opportunities for BD to introduce new products and expand its customer base.
2. Increasing demand for personalized medicine: BD can capitalize on the rising demand for personalized medicine by developing tailored diagnostics and treatment solutions.
3. Emerging markets: Expanding into emerging markets, especially in regions like Asia and Latin America, can provide BD with new avenues for growth.
Threats
1. Stringent regulations: Compliance with stringent regulations and obtaining necessary approvals for new products can pose challenges and delays for BD.
2. Pricing pressures: Intense competition and pricing pressures in the industry can impact BD's profit margins and overall financial performance.
3. Technological advancements: Rapid advancements in medical technology can render existing products obsolete, requiring BD to stay ahead of the curve.
Becton Dickinson and Co Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co Segments
Becton Dickinson and Co Revenue by Segment
3 Years
5 Years
10 Years
Max
Details
Becton Dickinson and Co Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Becton Dickinson and Co Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Becton Dickinson and Co historical P/E ratio, EBIT multiple, and P/S ratio
Becton Dickinson and Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Becton Dickinson and Co's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Becton Dickinson and Co's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Becton Dickinson and Co's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Becton Dickinson and Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co stock splits
Since 1993, a total of 8 shares have been converted from one Becton Dickinson and Co share.
Becton Dickinson and Co Dividend History
38 years of dividend payments · 9 consecutive increases
Becton Dickinson and Co dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Becton Dickinson and Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Becton Dickinson and Co forecasts and price targets in September 2026
Analyst Price Targets 2026Becton Dickinson and Co Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/13/2026 | Maintained | Sector Perform | 48 | |
| 8/7/2026 | Maintained | Equal Weight | 58 | |
| 8/7/2026 | Maintained | Sector Perform | 48 | |
| 8/7/2026 | Maintained | Neutral | 54 | |
| 8/7/2026 | Maintained | Buy | 46 | |
| 8/5/2026 | Maintained | Hold | 58 | |
| 7/6/2026 | Maintained | Outperform | 62 | |
| 5/11/2026 | Maintained | Overweight | 62 | |
| 5/8/2026 | Maintained | Equal Weight | 58 | |
| 5/4/2026 | Maintained | Hold | 58 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Becton Dickinson and Co Earnings Calls
Becton Dickinson and Co Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/5/2026 | 4.06USD | - | 5.11 BUSD | - | 2026 Q3 |
| 8/6/2026 | 3.14USD | 3.23USD | 4.89 BUSD | - | 2026 Q2 |
| 5/7/2026 | 2.78USD | 2.90USD | 4.67 BUSD | - | 2026 Q1 |
| 2/9/2026 | 2.21USD | 2.91USD | 5.15 BUSD | - | 2025 Q4 |
| 11/6/2025 | 3.92USD | 3.96USD | 5.91 BUSD | - | 2025 Q3 |
| 8/7/2025 | 3.40USD | 3.68USD | 5.49 BUSD | - | 2025 Q2 |
| 5/1/2025 | 3.28USD | 3.35USD | 5.35 BUSD | - | 2025 Q1 |
| 2/5/2025 | 3.00USD | 3.43USD | 5.10 BUSD | - | 2024 Q4 |
| 11/7/2024 | 3.77USD | 3.81USD | 5.38 BUSD | - | 2024 Q3 |
| 8/1/2024 | 3.31USD | 3.50USD | 5.08 BUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Becton Dickinson and Co stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Becton Dickinson and Co shareholder structure
| % | Name |
|---|---|
9.06502% | |
6.40902% | |
5.30910% | |
4.79112% | |
4.13440% | |
3.52652% |
Becton Dickinson and Co Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
77.00% | SEC ↗ | |
11.00% | SEC ↗ | |
8.77% | SEC ↗ | |
8.48% | SEC ↗ | |
7.75% | SEC ↗ | |
7.51% | SEC ↗ | |
7.50% | SEC ↗ | |
7.00% | SEC ↗ | |
6.39% | SEC ↗ | |
5.40% | SEC ↗ |
Becton Dickinson and Co Executives and Management Board
22 members · avg. age 60 · 27 % women
Mr. Thomas Polen (51)
Chairman of the Board, President, Chief Executive Officer · since 2014
17.31 M USD
Management
Mr. Christopher Delorefice (53)
Chief Financial Officer, Executive Vice President
Mr. Michael Garrison (56)
Executive Vice President, President - Medical Segment
Ms. Shana Neal (59)
Chief People Officer, Executive Vice President
Mr. Richard Byrd (57)
Executive Vice President, President - Interventional Segment
Mr. Antoine Ezell (55)
Executive Vice President, President, North America, Chief Marketing Officer
Ms. Michelle Quinn (56)
Executive Vice President, General Counsel
Board of Directors
Mr. Bertram Scott (74)
Lead Independent Director
Mr. Robert Andrew Eckert (63)
Independent Director
Ms. Catherine Burzik (74)
Independent Director
Mr. Jeffrey Henderson (60)
Independent Director
Mr. Christopher Jones (69)
Independent Director
Mr. Timothy Ring (67)
Independent Director
Becton Dickinson and Co Supply Chain
Becton Dickinson and Co Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.62 | 0.70 | 0.61 | ||
| 2 | -0.24 | 0.51 | 0.41 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Apria, Inc. | 0.41 | 0.41 | — | |
| 2 | -0.42 | -0.28 | — | ||
| 3 | -0.45 | -0.58 | — | ||
| 4 |  Ascendas Real Estate Investment Trust | -0.57 | -0.60 | — | |
| 5 | 0.10 | — | — |
Frequently asked questions about Becton Dickinson and Co
Becton Dickinson and Co (BD) operates under a diversified business model. As a leading global medical technology company, BD focuses on improving healthcare delivery by developing innovative solutions. The company's business model revolves around three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical offers a range of medical devices, such as injection systems and infusion therapy products, to enhance patient care. BD Life Sciences focuses on research and clinical laboratories, providing products for sample management and diagnostics. BD Interventional specializes in devices for minimally invasive procedures, contributing to improved patient outcomes. Becton Dickinson and Co's business model aims to address critical healthcare challenges by delivering reliable and effective solutions.
Becton Dickinson and Co is primarily active in the healthcare industry, specifically focusing on medical technology and devices.
The main competitors of Becton Dickinson and Co in the market are Thermo Fisher Scientific Inc., Cardinal Health Inc., and Johnson & Johnson.
Becton Dickinson and Co, commonly known as BD, is a leading global medical technology company. Founded in 1897, BD has a rich history and a strong reputation in the healthcare industry. The company specializes in medical devices, instrument systems, and reagents used by healthcare professionals for diagnostic and therapeutic purposes. With over a century of experience, BD has grown to become a trusted provider of innovative solutions that improve the quality of patient care. Headquartered in Franklin Lakes, New Jersey, BD operates in more than 190 countries worldwide, serving hospitals, laboratories, healthcare professionals, and patients with its diverse portfolio of products.
Becton Dickinson and Co has achieved several significant milestones throughout its history. The company pioneered the development of the first-ever sterile disposable syringe, which revolutionized healthcare practices worldwide. They also introduced the first medical-grade plastic blood collection tube, improving patient safety and sample integrity. Becton Dickinson and Co expanded its global presence by acquiring C.R. Bard, a leading medical technology company specializing in vascular, urology, and oncology products. This strategic move enhanced their product portfolio and market reach. Furthermore, the company has consistently focused on innovation, manufacturing high-quality medical devices, laboratory equipment, and diagnostic tools. Becton Dickinson and Co continues to drive advancements in healthcare, improving patient outcomes globally.
Becton Dickinson and Co is primarily present in numerous countries and regions across the globe. The company operates in various key markets, including the United States, Europe, Asia-Pacific, Latin America, and the Middle East. With its strong global presence, Becton Dickinson and Co has established a solid market foothold, allowing it to cater to a diverse range of customers and meet their healthcare needs effectively.
Becton Dickinson and Co represents a strong commitment to quality and innovation in the healthcare industry. The company's corporate philosophy revolves around improving patient outcomes through advanced medical technologies and solutions. By prioritizing patient safety and healthcare efficiency, Becton Dickinson has established itself as a leading provider of medical devices, diagnostic systems, and pharmaceutical systems. Their values include integrity, collaboration, and customer focus, emphasizing the importance of ethical behavior, teamwork, and meeting customer needs. Becton Dickinson and Co's dedication to advancing healthcare makes it a trusted partner for healthcare professionals worldwide.
Analysts currently set an average price target of 186.88 USD for the Becton Dickinson and Co stock (median: 190.00 USD), implying +1.7 % versus the latest price. The consensus is based on 21 analyst ratings.
21 analysts currently rate the Becton Dickinson and Co stock: 12 recommend buying, 9 holding and 0 selling. For 2026, analysts expect Becton Dickinson and Co to generate revenue of 19.29 B USD and earnings per share of 12.82 USD.
Converted at the current exchange rate, the Becton Dickinson and Co share trades at 161.30 EUR (183.82 USD).
The Becton Dickinson and Co share (BDX) is listed on 10 stock exchanges, including: NYSE (BDX), London (0R19.L), SIX (Zürich) (BDX.SW), XETRA (BOX.DE), Frankfurt (BOX.F), München (BOX.MU), Düsseldorf (BOX.DU), Wien (BDX.VI).
Becton Dickinson and Co. (BD) is a global leading medical technology company that specializes in diagnostics, instruments, and systems for medical therapy, laboratories, and life science research. The company is headquartered in New Jersey, USA, and operates in over 190 countries worldwide. The company is divided into three main business segments: BD Medical, BD Life Sciences, and BD Interventional. Each of these segments offers various products and services tailored to the needs of customers in the respective industries. BD Medical specializes in the development, manufacturing, and marketing of medical devices, insulin syringes, needles, and clinical diagnostic instruments. The goal of BD Medical is to help patients improve healthcare and reduce costs through innovative solutions. Some well-known products from BD Medical include BD Vacutainer blood collection systems, BD BACTEC systems for bacterial culture, BD Nexiva Closed I.V. catheter, and BD insulin syringes. BD Life Sciences specializes in the areas of biosciences and research. The company offers a wide range of products and services, including instruments and reagents for molecular biology, infectious diseases, and cancer research. BD Life Sciences supports scientists worldwide in the search for new diagnostic and treatment methods for diseases. Some well-known products from BD Life Sciences include BD FACSFlow Sheath Fluid, BD MAX systems for PCR amplification of DNA and RNA, and BD SurePath vials for cytological diagnosis. BD Interventional offers a variety of products and solutions for interventional medical technology. Key products from BD Interventional include catheters, stents, dilators, guide wires, and implantable devices such as pacemakers and defibrillators. The goal of BD Interventional is to provide surgeons and other medical professionals with the best possible tools and devices to safely and effectively treat patients and minimize the risk of complications. BD is also active in other business segments, such as the oil and gas industry and environmental analysis. The company also offers a wide range of professional services, training, and support to help professionals and customers effectively utilize BD's products and solutions. BD relies on continuous innovation to continuously improve its products and always provide customers with the best quality and performance. The company invests in research and development every year and collaborates closely with medical professionals and scientists to meet the demands of markets and customers. In summary, BD is a leading medical technology company focused on providing innovative products and solutions for the biosciences, clinical diagnostics, interventional medicine, and other industries. The company relies on a wide range of products and services, as well as continuous innovation and collaboration. With its global presence and commitment to quality and performance, BD positions itself as one of the key providers for the medical industry.
The expected revenue of Becton Dickinson and Co is 19.29 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Becton Dickinson and Co is 3.66 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Becton Dickinson and Co is currently 14.34. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Becton Dickinson and Co stock.
The price-to-sales ratio (P/S) of Becton Dickinson and Co is currently 2.72. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Becton Dickinson and Co stock.
The Eulerpool Quality Score for Becton Dickinson and Co is 4/10.
The ISIN of Becton Dickinson and Co is US0758871091. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Becton Dickinson and Co is 857675. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Becton Dickinson and Co is BDX. The ticker symbol is used to trade Becton Dickinson and Co shares on the stock exchange.
Over the past 12 months, Becton Dickinson and Co paid a dividend of 4.17 USD . This corresponds to a dividend yield of about 2.27 %. For the coming 12 months, Becton Dickinson and Co is expected to pay a dividend of 4.40 USD.
The current dividend yield of Becton Dickinson and Co is 2.27 %.
Becton Dickinson and Co pays a dividend, distributed in the months of December, March, June, September.
Becton Dickinson and Co paid dividends every year for the past 52 years.
For the upcoming 12 months, dividends amounting to 4.40 USD are expected. This corresponds to a dividend yield of 2.39 %.
Becton Dickinson and Co is assigned to the 'Health' sector.
In the year 2025, Becton Dickinson and Co distributed 4.17 USD as dividends.
The dividends of Becton Dickinson and Co are distributed in USD.
Becton Dickinson and Co stock
Becton Dickinson and Co Peer Group
Becton Dickinson and Co Ticker
Becton Dickinson and Co FIGI
All fundamentals and in-depth analysis of Becton Dickinson and Co
Our stock analysis for Becton Dickinson and Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Becton Dickinson and Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.